Home › Graft-Versus-Host Disease › Kansas
Graft-Versus-Host Disease clinical trials in Kansas
3 studies for Graft-Versus-Host Disease are looking for participants at sites in Kansas.
A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)
- University of Kansas Hospital Authority, Kansas City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 20, 2026 · NCT06615050Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
- University of Kansas Cancer Center, Westwood
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Mar 25, 2026 · NCT03533816A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- University of Kansas Cancer Center-Westwood, Westwood
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT06619561From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.